SCHEMBL24862154

SCHEMBL24862154

CCCC(C)(O)CCCn1nc(-c2ccc(CNC(=O)c3ccccc3OC)cc2)c2c(N)ncnc21

nearest known ligand 0.72

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 10/20 0.72
▸ EGFR P00533 19/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18665661 0.84 BTK (1.00) BTKEGFR
SCHEMBL21316378 0.83 EGFR (0.79) BTKEGFR
SCHEMBL18665709 0.82 EGFR (1.00) BTKEGFR
SCHEMBL18665651 0.82 EGFR (1.00) BTKEGFR
SCHEMBL18665707 0.82 EGFR (1.00) BTKEGFR
SCHEMBL18665700 0.79 BTK (0.81) BTKEGFR
SCHEMBL18665600 0.79 EGFR (1.00) BTKEGFR
SCHEMBL29617737 0.79 EGFR (1.00) BTKEGFR
SCHEMBL24862190 0.78 EGFR (0.68) BTKEGFR
SCHEMBL18665605 0.76 EGFR (1.00) BTKEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4116303-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER Loxo Oncology, Inc. (US) 2023-01-11 — — EP disclosed
Send feedback